select a format

Single User License
USD 2000 INR 128080
Site License
USD 4000 INR 256160
Corporate User License
USD 6000 INR 384240

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Anemia in Chronic Kidney Disease Renal Anemia-Pipeline Review, H1 2016

Anemia in Chronic Kidney Disease Renal Anemia-Pipeline Review, H1 2016


  • Products Id :- GMDHC8171IDB
  • |
  • Pages: 131
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Review, H1 2016', provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anemia in Chronic Kidney Disease (Renal Anemia) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anemia in Chronic Kidney Disease (Renal Anemia)

The report reviews pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics and enlists all their major and minor projects

The report assesses Anemia in Chronic Kidney Disease (Renal Anemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anemia in Chronic Kidney Disease (Renal Anemia)

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anemia in Chronic Kidney Disease (Renal Anemia)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anemia in Chronic Kidney Disease (Renal Anemia) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Anemia in Chronic Kidney Disease (Renal Anemia) Overview 10

Therapeutics Development 11

Pipeline Products for Anemia in Chronic Kidney Disease (Renal Anemia)-Overview 11

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics under Development by Companies 12

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Anemia in Chronic Kidney Disease (Renal Anemia)-Products under Development by Companies 19

Anemia in Chronic Kidney Disease (Renal Anemia)-Companies Involved in Therapeutics Development 21

3SBio Inc. 21

Acceleron Pharma, Inc. 22

Akebia Therapeutics, Inc. 23

Amgen Inc. 24

Bayer AG 25

BIOCAD 26

CCM Duopharma Biotech Bhd. 27

Chong Kun Dang Pharmaceutical Corp. 28

CJ HealthCare Corp. 29

Daiichi Sankyo Company, Limited 30

Dr. Reddy's Laboratories Limited 31

Eli Lilly and Company 32

FibroGen, Inc. 33

GlaxoSmithKline Plc 34

Intas Pharmaceuticals Ltd. 35

Japan Tobacco Inc. 36

JCR Pharmaceuticals Co., Ltd. 37

Jiangsu Hansoh Pharmaceutical Co., Ltd. 38

LG Life Science LTD. 39

Medgenics, Inc. 40

Myungmoon pharmaceutical Co., Ltd. 41

Panacea Biotec Limited 42

Pfizer Inc. 43

PharmaEssentia Corporation 44

Pieris Pharmaceuticals, Inc. 45

Sandoz International GmbH 46

Zydus Cadila Healthcare Limited 47

Anemia in Chronic Kidney Disease (Renal Anemia)-Therapeutics Assessment 48

Assessment by Monotherapy Products 48

Assessment by Target 49

Assessment by Mechanism of Action 51

Assessment by Route of Administration 53

Assessment by Molecule Type 55

Drug Profiles 57

daprodustat-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

darbepoetin alfa-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

darbepoetin alfa-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

darbepoetin alfa-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

darbepoetin alfa-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

darbepoetin alfa-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

darbepoetin alfa-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

darbepoetin alfa-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

darbepoetin alfa-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

darbepoetin alfa-Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

DS-1093-Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

EPO-018B-Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

epoetin alfa-Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

epoetin alfa-Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

epoetin zeta-Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

FG-2216-Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

JTZ-951-Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

LBDE-Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

LY-3113593-Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MDGN-201-Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

MMP-0101-Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

molidustat-Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

P-1116-Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

PEG-EPO-Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Peg-EPO-Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

PEG-EPO-Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

PRS-080-Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Recombinant Protein for Renal Anemia-Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

roxadustat-Drug Profile 96

Product Description 96

Mechanism Of Action 96

R&D Progress 96

Small Molecule to Inhibit HIF-PH for Renal Anemia-Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

sotatercept-Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

SSS-06-Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

vadadustat-Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects 116

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products 117

Anemia in Chronic Kidney Disease (Renal Anemia)-Product Development Milestones 118

Featured News & Press Releases 118

May 23, 2016: Akebia Announces Positive Vadadustat Data Demonstrating No Clinically Significant Drug-Drug Interaction 118

May 05, 2016: Akebia Provides Update On Phase 3 INNO2VATE Program For Vadadustat 118

Apr 26, 2016: Akebia Therapeutics Announces Presentation of Vadadustat Phase 2 Dialysis Data at Upcoming National Kidney Foundation 2016 Spring Clinical Meetings 119

Apr 08, 2016: Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's nephrology indication 119

Mar 09, 2016: Akebia Prevails in European Patent Dispute and Preserves Access to Key Market for Vadadustat 120

Feb 16, 2016: FibroGen Publishes Encouraging Phase 2 Anemia Data Demonstrating Roxadustat's Ability to Maintain Hemoglobin Levels in Patients With Chronic Kidney Disease 120

Jan 04, 2016: Akebia Initiates Phase 3 PRO2TECT Program 122

Oct 28, 2015: Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting 123

Aug 12, 2015: Nephrology Dialysis Transplantation Reports Phase 2 Data Of Investigational Orally Active Hif-Phi Roxadustat (Fg-4592) Shows Improved Hemoglobin Levels In Non-Dialysis Ckd Subjects With Anemia 125

Jul 15, 2015: Medgenics Announces First Patient Enrolled in U.S.-Based Phase 2 Clinical Trial of TARGT-EPO for Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis 125

May 26, 2015: Akebia Therapeutics Announces Presentation of AKB-6548 Phase 2b Data at the 52nd ERA-EDTA Annual Congress 126

Mar 16, 2015: Akebia Announces Presentation of Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia at WCN 126

Mar 11, 2015: Bayer to Present Latest Clinical Data On Molidustat 128

Mar 10, 2015: Akebia Announces Completion of Enrollment in Phase 2 Trial of AKB-6548 in Dialysis Patients with Anemia Related to Chronic Kidney Disease 128

Oct 15, 2014: Medgenics Reports Positive Initial Clinical Data From Clinical Study Of MDGN-201 129

Appendix 130

Methodology 130

Coverage 130

Secondary Research 130

Primary Research 130

Expert Panel Validation 130

Contact Us 130

Disclaimer 131

List of Figures

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Products, H1 2016 17

Assessment by Monotherapy Products, H1 2016 48

Number of Products by Top 10 Targets, H1 2016 49

Number of Products by Stage and Top 10 Targets, H1 2016 49

Number of Products by Top 10 Mechanism of Actions, H1 2016 51

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 51

Number of Products by Routes of Administration, H1 2016 53

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 53

Number of Products by Molecule Types, H1 2016 55

Number of Products by Stage and Molecule Types, H1 2016 55

List of Tables

Number of Products under Development for Anemia in Chronic Kidney Disease (Renal Anemia), H1 2016 11

Number of Products under Development by Companies, H1 2016 13

Number of Products under Development by Companies, H1 2016 (Contd..1) 14

Comparative Analysis by Late Stage Development, H1 2016 15

Comparative Analysis by Clinical Stage Development, H1 2016 16

Comparative Analysis by Early Stage Development, H1 2016 17

Comparative Analysis by Unknown Stage Development, H1 2016 18

Products under Development by Companies, H1 2016 19

Products under Development by Companies, H1 2016 (Contd..1) 20

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by 3SBio Inc., H1 2016 21

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Acceleron Pharma, Inc., H1 2016 22

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Akebia Therapeutics, Inc., H1 2016 23

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Amgen Inc., H1 2016 24

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Bayer AG, H1 2016 25

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by BIOCAD, H1 2016 26

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CCM Duopharma Biotech Bhd., H1 2016 27

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016 28

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by CJ HealthCare Corp., H1 2016 29

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Daiichi Sankyo Company, Limited, H1 2016 30

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 31

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Eli Lilly and Company, H1 2016 32

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by FibroGen, Inc., H1 2016 33

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by GlaxoSmithKline Plc, H1 2016 34

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Intas Pharmaceuticals Ltd., H1 2016 35

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Japan Tobacco Inc., H1 2016 36

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by JCR Pharmaceuticals Co., Ltd., H1 2016 37

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 38

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by LG Life Science LTD., H1 2016 39

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Medgenics, Inc., H1 2016 40

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Myungmoon pharmaceutical Co., Ltd., H1 2016 41

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Panacea Biotec Limited, H1 2016 42

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pfizer Inc., H1 2016 43

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by PharmaEssentia Corporation, H1 2016 44

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Pieris Pharmaceuticals, Inc., H1 2016 45

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Sandoz International GmbH, H1 2016 46

Anemia in Chronic Kidney Disease (Renal Anemia)-Pipeline by Zydus Cadila Healthcare Limited, H1 2016 47

Assessment by Monotherapy Products, H1 2016 48

Number of Products by Stage and Target, H1 2016 50

Number of Products by Stage and Mechanism of Action, H1 2016 52

Number of Products by Stage and Route of Administration, H1 2016 54

Number of Products by Stage and Molecule Type, H1 2016 56

Anemia in Chronic Kidney Disease (Renal Anemia)-Dormant Projects, H1 2016 116

Anemia in Chronic Kidney Disease (Renal Anemia)-Discontinued Products, H1 2016 117

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3SBio Inc.

Acceleron Pharma, Inc.

Akebia Therapeutics, Inc.

Amgen Inc.

Bayer AG

BIOCAD

CCM Duopharma Biotech Bhd.

Chong Kun Dang Pharmaceutical Corp.

CJ HealthCare Corp.

Daiichi Sankyo Company, Limited

Dr. Reddy's Laboratories Limited

Eli Lilly and Company

FibroGen, Inc.

GlaxoSmithKline Plc

Intas Pharmaceuticals Ltd.

Japan Tobacco Inc.

JCR Pharmaceuticals Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

LG Life Science LTD.

Medgenics, Inc.

Myungmoon pharmaceutical Co., Ltd.

Panacea Biotec Limited

Pfizer Inc.

PharmaEssentia Corporation

Pieris Pharmaceuticals, Inc.

Sandoz International GmbH

Zydus Cadila Healthcare Limited

Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutic Products under Development, Key Players in Anemia in Chronic Kidney Disease (Renal Anemia) Therapeutics, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Overview, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline, Anemia in Chronic Kidney Disease (Renal Anemia) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com